After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
CytomX Therapeutics Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of CytomX Therapeutics Inc is $674.50M. A total of 4.72 million shares were traded on the day, compared to an average of 3.73M shares.
In the most recent transaction, Ogden Christopher sold 10,614 shares of CTMX for 2.69 per share on Jun 16 ’25. After the transaction, the Chief Financial Officer now owns 226,271 company shares. In a previous transaction on Jun 13 ’25, Ogden Christopher sold 1,641 shares at 2.95 per share. CTMX shares that Chief Financial Officer owns now total 199,385.
Among the insiders who sold shares, BELVIN MARCIA disposed of 13,884 shares on Jun 16 ’25 at a per-share price of $2.69. This resulted in the SVP, Chief Scientific Officer holding 272,252 shares of CTMX after the transaction. In another insider transaction, McCarthy Sean A. sold 55,511 shares at $2.69 per share on Jun 16 ’25. Company shares held by the CEO now total 1,089,684.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, CTMX has a high of $4.16 and a low of $0.40.
As of this writing, CTMX has an earnings estimate of -$0.04 per share for the current quarter. EPS was calculated based on a consensus of 7.0 estimates, with a high estimate of $0.0 per share and a lower estimate of -$0.09. The company reported an EPS of $0.07 in the last quarter
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. CTMX’s latest balance sheet shows that the firm has $305.23M in Cash & Short Term Investments as of fiscal 2021. There were $21.67M in debt and $77.87M in liabilities at the time. Its Book Value Per Share was $0.73, while its Total Shareholder’s Equity was -$459.00k.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CTMX is Buy with a score of 4.56.
